Susquehanna International Group
IBO

Susquehanna International Group’s Impact BioMedical IBO Stock Holding History

Susquehanna International Group’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,501
Closed -$8.33K – 14360
2025
Q4 		$8.33K Sell
16,501
-4,461
-21% -$2.36K ﹤0.01% 12071
2025
Q3 		$13.9K Sell
20,962
-9,862
-32% -$6.22K ﹤0.01% 12081
2025
Q2 		$19.9K Buy
+30,824
New +$17.3K ﹤0.01% 12336

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Susquehanna International Group's IBO Position: Q1 2026 in Review

Susquehanna International Group sold out of Impact BioMedical (IBO) in Q1 2026, closing a stake of 16,501 shares — an estimated $8.33K sold.

Susquehanna International Group first reported a position in IBO in Q2 2025 and held it in 3 quarters. The position peaked at $19.9K in Q2 2025. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • Susquehanna International Group reported no remaining Impact BioMedical position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 16,501 Impact BioMedical shares in Q1 2026, an estimated $8.33K.
  • Susquehanna International Group first reported a position in Impact BioMedical in Q2 2025 and held it in 3 quarters.
  • Susquehanna International Group's Impact BioMedical position peaked at $19.9K in Q2 2025.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.